Home › Compare › YMFCF vs ABBV
YMFCF yields 2.10% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, YMFCF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of YMFCF + ABBV for your $10,000?
Yamashin-Filter Corp. operates as a filter manufacturer. The company manufactures, develops, and sells filters for construction and agricultural machines, drive-train, fuel systems and various filter products for industrial and precision machines, and industrial filter related parts; and nano filter products. Its construction machinery filters include hydraulic fluid filters to protect hydraulic cylinders, controls, and hydraulic systems used on machinery; engine oil filters that are used in various types of engines to remove contaminants from oil; fuel filters used to construction machinery to remove contaminants and water from diesel fuel; transmission filters for on-highway/off-highway applications; industrial filters to filter hydraulic fluid, lubricating oil, and other liquids in a range of industrial machinery; and process filters, which are used for filtration and separation in manufacturing processes across a range of industries, including electronic parts, precision components, LCD displays, and food products. The company also provides various types of air filters for a range of settings, such as office buildings, factories, machines, and vehicles; and medical-grade masks and replacement inner sheets that are made using YAMASHIN NANO FILTER. It operates in Japan, Asia, North America, and Europe. The company was formerly known as Yamashin Industry Inc. and changed its name to Yamashin-Filter Corp. in October 2005. Yamashin-Filter Corp. was incorporated in 1956 and is headquartered in Yokohama, Japan.
Full YMFCF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.